Non-animal methodologies within biomedical research and toxicity testing

Altex

Volumn 25, Issue 3, 2008, Pages 213-231

  Knight, Andrew ^a  

^a Animal Consultants International   (United Kingdom)

Author keywords

3Rs; Alternative; Animal experimentation; Animal model; Biomedical research; Toxicity testing

Indexed keywords

HYDROXYAPATITE; TGN 1412; DRUG;

ANIMAL TESTING REPLACEMENT; ATTITUDE; BRAIN TISSUE; CELL TRANSFORMATION; COMPUTER MODEL; DNA MICROARRAY; DRUG HYPERSENSITIVITY; DRUG RESEARCH; EMBRYONIC STEM CELL; EXPERT SYSTEM; GENE EXPRESSION PROFILING; GENETIC ENGINEERING; GENOMICS; GENOTOXICITY; HUMAN; LIVER CELL CULTURE; MEDICAL RESEARCH; METABOLIC ACTIVATION; NONHUMAN; ORGAN CULTURE; PHYSICAL CHEMISTRY; POLICY; PSYCHOLOGY; QUALITY CONTROL; REVIEW; SOCIOLOGY; STEM CELL; STRUCTURE ACTIVITY RELATION; TISSUE CULTURE; TOXICITY TESTING; ANIMAL; ANIMAL TESTING ALTERNATIVE; ARTICLE; CHEMISTRY; CHICK EMBRYO; DISEASE MODEL; ETHICS; LEGAL ASPECT; METHODOLOGY; TISSUE CULTURE TECHNIQUE; TOXICOGENETICS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOMEDICAL RESEARCH; CHICK EMBRYO; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; EXPERT SYSTEMS; GENETIC ENGINEERING; HUMANS; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE CULTURE TECHNIQUES; TOXICITY TESTS; TOXICOGENETICS;

EID: 58949084341     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: 10.14573/altex.2008.3.213     Document Type: Review

References (163)

1. Aardema, M. and MacGregor, J. T. (2002). Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "omics" technologies. Mutat. Res. 499, 13-25.
2. Akyüz, N. and Wiesmüller, L. (2003). Proof of principle: detection of genotoxicity by a fluorescence-based recombination test in mammalian cells. ALTEX 20(2), 77-84.
3. Amacher, D. E. and Zelljadt, I. (1983). The morphological transformation of Syrian hamster embryo cells by chemicals reportedly nonmutagenic to Salmonella typhimurium. Carcinogenesis 4, 291-295.
4. Andersen, M. E. (1991). Physiological modelling of organic compounds. Ann. Occup.Hyg. 35, 309-321.
5. Anon (1986). Animals (Scientific Procedures) Act 1986. London, UK: HMSO.
6. Ashby, J. and Tennant, R. W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutation Research 257, 229-306. Erratum in Mutation Research 1994, 317, 175.
7. Balls, M., Blaauboer, B., Brusick, D. et al. (1990). Report and recommendations of the CAAT/ERGATT workshop on the validation of toxicity test procedures. ATLA 18, 313-337.
8. Balls, M. (1994). Replacement of animal procedures: alternatives in research, education and testing. ATLA 28, 193-211. (Pubitemid 24228565)
9. Balls, M. (2004). Are animal tests inherently valid? ATLA 32 Suppl. 1B, 755-758.
10. Balls, M. and Combes, R. (2006). Validation via weight-of-evidence approaches. ALTEX 23 Sp. Issue, 332-335.
11. Barker, A. T., Jalinous, R. and Freeston, I. L. (1985). Non-invasive magnetic stimulation of the human motor cortex. Lancet 1, 1106-1107. (Pubitemid 15075547)
12. Benigni, R., Passerini, L. and Rodomonte, A. (2003). Structure-activity relationships for the mutagenicity and carcinogenicity of simple and alpha-beta unsaturated aldehydes. Environ. Mol. Mutagen. 42, 136-143. (Pubitemid 37429751)
13. Besaratinia, A., Kleinjans, J. C. and Van Schooten, F. J. (2002). Biomonitoring of tobacco smoke carcinogenicity by dosimetry of DNA adducts and genotyping and phenotyping of biotransformational enzymes: a review on polycyclic aromatic hydrocarbons. Biomarkers 7, 209-229. (Pubitemid 34678837)
14. Bhogal, N. and Combes, R. (2006). TGN1412: time to change the paradigm for the testing of new pharmaceuticals. ATLA 34, 225-239. (Pubitemid 43844405)
15. Blaauboer, B. J., Hermens, J. and van Eijkeren, J. (2006). Estimating acute toxicity based on in vitro cytotoxicity: role of biokinetic modelling. ALTEX 23 Sp. Issue, 250-253.
16. Bremer, S., Worth, A. P., Paparella, M. et al. (2001). Establishment of an in vitro reporter gene assay for developmental cardiac toxicity. Toxicol. In Vitro 15, 215-223.
17. Bremer, S., Pellizzer, C., Hoffmann, S. et al. (2007). The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. Curr. Pharm. Des. 13(29), 3047-3058. (Pubitemid 350130970)
18. Broadhead, C. and Bottrill, K. (1997). Strategies for replacing animals in biomedical research. Mol. Med. Today 3(11), 483-487. (Pubitemid 27505481)
19. Brown, N. A. (1987). Teratogenicity testing in vitro: status of validation studies. Arch. Toxicol. Suppl. 11, 105-114. (Pubitemid 17091550)
20. Brown, N. A., Spielmann, H., Bechter, R. et al. (1995). Screening chemicals for reproductive toxicity: the current alternatives. ATLA 23, 868-882.
21. Brusick, D. J. (1977). In vitro mutagenesis assays as predictors of chemical carcinogenesis in mammals. Clin. Toxicol. 10, 79-109.
22. Buesen, R., Visan, A., Genschow, E. et al. (2004). Trends in improving the embryonic stem cell test (EST): an overview. ALTEX 21(1), 15-22. (Pubitemid 38979464)
23. Cahill, P. A., Knight, A. W., Billinton, N. et al. (2004). The GreenScreen genotoxicity assay: a screening validation programme. Mutagenesis 19, 105-119. (Pubitemid 38380287)
24. CDER, Center for Drug Evaluation and Research, US Department of Health and Human Services Food and Drug Administration (2006). Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. Rockville, MD, US: CDER.
25. Charles, G. D. (2004). In vitro models in endocrine disrupter screening. ILAR J. 45(4), 494-501.
26. Collins F. S., Gray, G. M. and Bucher, J. R. (2008). Transforming environmental health protection. Science 319, 906-907.
27. Comber, M. H., Walker, J. D., Watts, C. and Hermens, J. (2003). Quantitative structure-activity relationships for predicting potential ecological hazard of organic chemicals for use in regulatory risk assessments. Environ. Toxicol. Chem. 22, 1822-1828. (Pubitemid 37337307)
28. Combes, R., Balls, M., Curren, R. et al. (1999). Cell transformation assays as predictors of human carcinogenicity: The report and recommendations of ECVAM Workshop 39. ATLA 27, 745-767. (Pubitemid 29503028)
29. Combes, R. D. (2000). The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens. Toxicol. In Vitro 14, 387.
30. Combes, R. D., Berridge, T., Connelly, J. et al. (2003). Early microdose drug studies in human volunteers can minimise animal testing - proceedings of a workshop organised by Volunteers in Research and Testing. Eur. J. Pharm. Sci. 19, 1-11. (Pubitemid 36506932)
31. Combes, R. D., Balls, M., Bansil, L. et al. (2004). The Third FRAME Toxicity Committee: Working toward greater implementation of alternatives in toxicity testing. ATLA 32 Suppl. 1B, 635-642.
32. Combes, R. (2007). Developing, validating and using test batteries and tiered (hierarchical) testing schemes. ATLA 35, 375-378. (Pubitemid 350271753)
33. Combes, R., Grindon, C., Cronin, M. T. et al. (2007). Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation. ATLA 35(2), 267-287. (Pubitemid 46883166)
34. Cone, J. E. and Rosenberg, J. (1990). Medical surveillance and biomonitoring for occupational cancer endpoints. Occup. Med. 5, 563-581.
35. Conolly, R. B., Reitz, R. H., Clewell, H. J. 3rd and Andersen, M. E. (1988). Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model of chemical carcinogenesis. Toxicol. Lett. 43, 189-200.
36. Cosson, P. (2007). A non-mammalian system to study bacterial infections. ALTEX 24 Sp. Issue, 78-79.
37. Council of Europe (1986). European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (ETS 123). Strasbourg, France: Council of Europe.
38. Crespi, C. (1995). Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26, 180-235.
39. Cronin, M. T., Dearden, J. C., Walker, J. D. and Worth, A. P. (2003). Quantitative structure-activity relationships for human health effects: commonalities with other endpoints. Environ. Toxicol. Chem. 22, 1829-1843. (Pubitemid 37337308)
40. Dearfield, K. L., Auletta, A. E., Cimino, M. C. and Moore, M. M. (1991). Considerations in the U.S. Environmental Protection Agency's testing approach for mutagenicity. Mutat. Res. 258, 259-283.
41. Department of Health (DH) (UK): Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment (2000). Guidance on a Strategy for Testing of Chemicals for Mutagenicity. London, UK: DH.
42. DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151-185. (Pubitemid 36279392)
43. EC (European Commission) (2003). IP/03/969. European Commission proposes strict ethical guidelines on EU funding of human embryonic stem cell research.
44. ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals) (1997). Aneuploidy: ECETOC Monograph No. 27. Brussels, Belgium: ECETOC.
45. ECHA (European Chemicals Agency) (2008). Guidance on Registration. Version 1.2. Helsinki, Finland: ECHA.
46. Eckert, J. (1997). Alternatives to animal experimentation in parasitology. Vet. Parasitol. 71(2-3), 99-120. (Pubitemid 27323753)
47. ECVAM (European Centre for the Validation of Alternative Methods), Joint Research Centre, European Commission Directorate General (undated). Validated methods. http://ecvam.jrc.it/, accessed 31. Aug. 2008.
48. Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A. and Ahr, H. J. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637(1-2), 23-39. (Pubitemid 350256758)
49. EPA (Environmental Protection Agency) (US). (2007). OncoLogic™ - A computer system to evaluate the carcinogenic potential of chemicals.
50. EPA (Environmental Protection Agency) (US). (Updated 20 Mar. 2008). High Production Volume (HPV) Challenge. http://www.epa.gov/HPV/, accessed 9 Jun. 2008.
51. Epstein, S. S. (1998). The Politics of Cancer Revisited. Fremont Center, NY, USA: East Ridge Press.
52. Farr, S. and Dunn, R. T. (1999). Concise review: gene expression applied to toxicology. Toxicol. Sci. 50, 1-9. (Pubitemid 29344505)
53. Fenner-Crisp, P. A., Maciorowski, A. F. and Timm, G. E. (2000). The endocrine disrupter screening program developed by the U.S. Environmental Protection Agency. Ecotoxicology 9(1-2), 85-91.
54. Fleischer, M. (2007). Testing cost and testing capacity according to REACH requirements - results of a survey of independent and corporate GLP laboratories in the EU and Switzerland. J. Business Chem. 4, 96-114.
55. Gallas, M. M., Abeleira, M. T., Fernandez, J. R. and Burguera, M. (2005). Three-dimensional numerical simulation of dental implants as orthodontic anchorage. Eur. J. Orthod. 27, 12-16. (Pubitemid 41219066)
56. Genschow, E., Spielmann, H., Scholz, G. et al. (2002). The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. ATLA 30(2), 151-176. (Pubitemid 34534620)
57. Genschow, E., Spielmann, H., Scholz, G. et al. (2004). Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. ATLA 32(3), 209-244. (Pubitemid 39517737)
58. Germani, M., Crivori, P., Rocchetti, M. et al. (2007). Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur. J. Pharm. Sci. 31(3-4), 190-201.
59. Gerner, I., Barratt, M. D., Zinke, S. et al. (2004). Development and prevalidation of a list of structure-activity relationship rules to be used in expert systems for prediction of the skin-sensitising properties of chemicals. ATLA 32(5), 487-509. (Pubitemid 40128844)
60. Gold, L. S., Manley, N. B., Slone, T. H. and Rohrbach, L. (1999). Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. Environ. Health Perspect. 107 Suppl. 4, 527-600.
61. Goodman, J. I. (2001). A perspective on current and future uses of alternative models for carcinogenicity testing. Toxicol. Pathol. 29 Suppl. 1, 173-176. (Pubitemid 33026805)
62. Green, S., Goldberg, A. M. and Zurlo, J. (2001). The TestSmart-HPV program: development of an integrated approach for testing high production volume chemicals. Regul. Toxicol. Pharmacol 33(2), 105-109. (Pubitemid 32466675)
63. Green, S. and Goldberg, A. M. (2004). TestSmart and toxic ignorance. ATLA 32 Suppl. 1A, 359-363. (Pubitemid 38843539)
64. Gruber, F. P. and Hartung, T. (2004). Alternatives to animal experimentation in basic research. ALTEX 21 Suppl. 1, 3-31. (Pubitemid 40074944)
65. Guengerich, F. P. (2006). Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8(1), E101-E111.
66. Hartung, T. (2007). Food for thought ... on cell culture. ALTEX 24(3), 143-147.
67. Hartung, T. (2008a). Food for thought ... on animal tests. ALTEX 25(1), 3-9.
68. Hartung, T. (2008b). Thoughts on limitations of animal models. Parkinsonism Relat. Disord., (in press).
69. Hartung, T. and Leist, M. (2008). Food for thought...on the evolution of toxicology and the phasing out of animal testing. ALTEX 25(2), 91-96.
70. Hastwell, P. W., Chai, L. L., Roberts, K. J. et al. (2006). High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen® HC GADD45a-GFP genotoxicity assay. Mutat. Res. 607, 160-175. (Pubitemid 44107783)
71. Heindl, C., Hess, A. and Brune, K. (2008). Refinement and reduction in animal experimentation: options for new imaging techniques. ALTEX 25(2), 121-125.
72. Hendriksen, C. F. (2006). Towards eliminating the use of animals for regulatory required vaccine quality control. ALTEX 23(3), 187-190 (Pubitemid 44696389)
73. Huggins, J. (2003). Alternatives to animal testing: research, trends, validation, regulatory acceptance. ALTEX 20 Suppl. 1, 3-61.
74. Jennings, P., Koppelstaetter, C., Pfaller, W. et al. (2004). Assessment of a new cell culture perfusion apparatus for in vitro chronic toxicity testing. Part 2: Toxicological evaluation. ALTEX 21(2), 61-66. (Pubitemid 38979272)
75. Kirkland, D., Aardema, M., Henderson, L. and Muller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584, 1-256. (Pubitemid 40922793)
76. Knight, A. (2007). Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. ATLA 35(6), 641-659.
77. Knight, A. (2008). 127 million non-human vertebrates used worldwide for scientific purposes in 2005. ATLA 36, in press.
78. Knight, A., Bailey, J. and Balcombe, J. (2006a). Animal carcinogenicity studies: 3. alternatives to the bioassay. ATLA 34(1), 39-48. (Pubitemid 43374070)
79. Knight, A., Bailey, J. and Balcombe, J. (2006b). Animal carcinogenicity studies: 1. poor human predictivity. ATLA 34(1), 19-27. (Pubitemid 43378977)
80. Kolossov, E., Fleischmann, B. K., Liu, Q. et al. (1998). Functional characteristics of ES cell-derived cardiac precursor cells identified by tissue-specific expression of the green fluorescent protein. J. Cell. Biol. 143(7), 2045-2056. (Pubitemid 29022623)
81. Kramer, J. A., Curtiss, S. W., Kolaja, K. L. et al. (2004). Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 17, 463-470. (Pubitemid 38506980)
82. Kramer, B. S., Wilentz, J., Alexander, D. et al. (2006). Getting it right: being smarter about clinical trials: a major NIH meeing led to recommendations for conducting better clinical trials. PLoS Medicine 3, 144. (Pubitemid 43987815)
83. Kulpa-Eddy, J. A. (2006). Overview of the regulatory requirements for the consideration of alternatives. ALTEX 23 Sp. Issue, 200-202.
84. Landolph, R. A. (1985). Chemical transformation in C3H10T1/2 CC118 mouse embryo fibroblasts: historical background, assessment of transformation assay and evolution and optimization of the transformation assay protocol. In T. Kakunaga and H. Yamasaki (eds.), Transformation assay of established cell lines: Mechanisms and Application, IRAC Scientific Publications No.67 (185-203). Lyon, France: Intnl. Agency for Res. on Cancer.
85. Langley, G., Harding, G., Hawkins, P. et al. (2000). Volunteer studies replacing animal experiments in brain research: report and recommendations of a volunteers in research and testing workshop. ATLA 28, 315-331.
86. Langley, G., Evans, T., Holgate, S. T. and Jones, A. (2007). Replacing animal experiments: choices, chances and challenges. BioEssays 29(9), 918-926. (Pubitemid 47424901)
87. Langsch, A. and Nau, H. (2006). Metabolic activation for in vitro systems. ALTEX 23 Sp. Issue, 353-357.
88. Larson, J. A. (2006). The animal welfare information center: helping the community meet the information requirement of the 3Rs. ALTEX 23 Sp. Issue, 192-196.
89. Lavé, T., Parrott, N., Grimm, H. P. et al. (2007). Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37(10-11), 1295-1310. (Pubitemid 350035528)
90. Lazarou, J. and Pomeranz, B. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Amer. Med. Assoc. 279, 1200-1205. (Pubitemid 28193431)
91. Leib, S. L. (2007). An in vitro model of central nervous system infection and regeneration: neuronal stem cells as targets of brain damage and regenerative therapies in bacterial meningitis. ALTEX 24 Sp. Issue, 90-92.
92. Leist, M., Kadereit, S. and Schildknecht, S. (2008a). Food for thought ... on the real success of 3R approches. ALTEX 25(1), 17-24.
93. Leist, M., Hartung, T. and Nicotera, P. (2008b). The dawning of a new age of toxicology. ALTEX 25(2), 103-114.
94. Li, A. P. (2005). Cell culture tool and method. U.S. Patent 20050101010.
95. Li, A. P. (2008a). Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties: general concepts and assay procedures. ALTEX 25(1), 33-42.
96. Li, A. P. (2008b). In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell coculture (IdMOC) technology. ALTEX 25(1), 43-49.
97. Lichtenberg-Frate, H., Schmitt, M., Geliert, G. and Ludwig, J. (2003). A yeast-based method for the detection of cytoand genotoxicity. Toxicol. In Vitro 17, 709-716.
98. Lilienblum, W., Dekant, W., Foth, H. et al. (2008). Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Arch. Toxicol. 82(4), 211-236.
99. Lockhart, D. J. and Winzeler, E. A. (2000). Genomics, gene expression and DNA arrays. Nature 405, 827-836. (Pubitemid 30407861)
100. Louekari, K., Sihvonen, K., Kuittinen, M. and Sømnes, V. (2006). In vitro tests within the REACH information strategies. ATLA 34(4), 377-386. (Pubitemid 44369439)
101. Luttun, A. and Verfaillie, C. M. (2006). A perspective on stem cells as a tool for in vitro testing. ALTEX 23 Sp. Issue, 388-392.
102. Mackerle, J. (2004). Finite element modelling and simulations in dentistry: a bibliography 1990-2003. Comp. Methods Biomech. Biomed. Eng. 7, 277-303.
103. MAP Coalition, Mandatory Alternatives Petition Coalition (2007). Petition to the US Food and Drug Administration for Mandatory Use of Non-Animal Methods in the Development and Approval of Drugs and Devices.
104. Matthews, E. J. and Contrera, J. F. (1998). A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul. Toxicol. and Pharmacol. 28, 242-264. (Pubitemid 29096166)
105. Matthews, R. A. (2008). Medical progress depends on animal models - doesn't it? J. R. Soc. Med. 101, 95-98.
106. Mauthe, R. J., Gibson, D. P., Bunch, R. T. and Custer, L. (2001). The Syrian hamster embryo (SHE) cell transformation assay: review of the methods and results. Toxicol. Pathol. 29 Suppl. 1, 138-146. (Pubitemid 33026801)
107. Metzger, J. M., Lin, W. I. and Samuelson, L. C. (1996). Vital staining of cardiac myocytes during embryonic stem cell cardiogenesis in vitro. Circ. Res. 78, 547-552. (Pubitemid 26106869)
108. MHRA, Medicines and Healthcare products Regulatory Agency (2006). Investigator's Brochure: TGN1412 humanized agonistic anti-CD28 monoclonal antibody. http://www.mhra.gov.uk/home/groups/es-foi/documents/foidisclosure/ con2023525.pdf, accessed 9 Jun. 2008.
109. Mitchell, I. de G. and Combes, R. D. (1997). In vitro genotoxicity and cell transformation assessment. In J.V. Castell and M.J. Gómez- Lechón (eds.), In Vitro Methods in Pharmaceutical Research (318-352). London, UK: Academic Press.
110. Mitterhauser, M. and Toegel, S. (2008). An in vitro model for the comparative evaluation of bone seeking pharmaceuticals. ALTEX 25(1), 51-55.
111. Monro, A. M. and MacDonald, J. S. (1998). Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation. Drug Safety 18, 309-319.
112. Montag, T., Spreitzer, I., Löschner, B. et al. (2007). Safety testing of cell-based medicinal products: opportunities for the monocyte activation test for pyrogens. ALTEX 24(2), 81-89.
113. Morton, D. B. (1995). Advances in refinement in animal experimentation over the past 25 years. ATLA 23, 812-822.
114. Morton, D. B. (1998). ANZCCART Facts Sheet. The importance of non-statistical design in refining animal experimentation. ANZCCART News 11(2), 12. Glen Osmond, SA, Australia: ANZCCART.
115. Murthy, B. (2007). Relevance of in vitro toxicology studies in risk assessment. ALTEX 24(3), 174-177.
116. Nahmias, Y. K., Gao, B. Z. and Odde, D. J. (2004). Dimensionless parameters for the design of optical traps and laser guidance systems. Appl. Opt. 43, 3999-4006.
117. NIH (National Institutes of Health) (2006). Information on clinical trials and human research studies.
118. Northwick Park Hospital (2006). Press Statement from Northwick Park Hospital, 5 April 2006.
119. NRC (National Research Council) (US) (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC, US: National Academies Press.
120. NTP (National Toxicology Program) (US) (2004). A National Toxicology Program for the 21st Century: A Roadmap for the Future. NC, US: NTP, National Institute of Environmental Health Sciences.
121. O'Connor, A. M. (1997). Barriers to regulatory acceptance. In L. F. M. van Zutphen and M. Balls (eds.), Animal Alternatives, Welfare and Ethics (1173-1176). Amsterdam, The Netherlands: Elsevier.
122. Odde, D. J. and Renn, M. J. (2000). Laser-guided direct writing of living cells. Biotechnol. Bioeng. 67, 312-318. (Pubitemid 30051328)
123. Paparella, M., Kolossov, E., Fleischmann, B. K. et al. (2002). The use of quantitative image analysis in the assessment of in vitro embryotoxicity endpoints based on a novel embryonic stem cell clone with endoderm-related GFP expression. Toxicol. In Vitro 16(5), 589-597. (Pubitemid 35223142)
124. Parry, E. M. and Parry, J. M. (1995). In vitro cytogenetics and aneuploidy. In D.H. Phillips and S. Venitt (eds.), Environmental Mutagenesis (121-139). Oxford, UK: Bios Scientific Publishers.
125. Pellizzer, C., Adler, S., Corvi, R. et al. (2004a). Monitoring of teratogenic effects in vitro by analysing a selected gene expression pattern. Toxicol. In Vitro 18(3), 325-335. (Pubitemid 38376366)
126. Pellizzer, C., Bello, E., Adler, S. et al. (2004b). Detection of tissue specific effects by methotrexate on differentiating mouse embryonic stem cells. Birth Defects Res. B. Dev. Reprod. Toxicol. 71(5), 331-341. (Pubitemid 39507101)
127. Pellizzer, C., Bremer, S. and Hartung, T. (2005). Developmental toxicity testing from animal towards embryonic stem cells. ALTEX 22(2), 47-57. (Pubitemid 40974877)
128. Pichler, W. J. (2007). Predicting drug hypersensitivity by in vitro tests. ALTEX 24 Sp. Issue, 49-52.
129. Pienta, R. J., Poiley, J. A. and Lebherz, W. B. 3rd (1977). Morphological transformation of early passage golden Syrian hamster embryo cells derived from cryopreserved primary cultures as a reliable in vitro bioassay for identifying diverse carcinogens. Int. J. Cancer 19, 642-655.
130. Pippin, J. J. (2008). "MAP" for improving drug testing: Mandatory Alternatives Petition urges FDA to require use of replacements to animal testing. Genetic Engineering and Biotechnology News, 28(5).
131. Purcell, W. M. and Atterwill, C. K. (1995). Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perspectives. Neurochem. Res. 20, 521-532.
132. Reznikoff, T., Bertram, J. S., Brankow, D. W. and Heidelberger, C. (1973). Quantitative and qualitative studies on chemical transformation of cloned C3H mouse embryo cells sensitive to post-confluence inhibition of cell division. Cancer Res. 33, 3239-3249.
133. Robinson, S., Delongeas, J.-L., Donald, E. et al. (2008). A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul. Toxicol. Pharmacol. 50, 345-352.
134. Rowan, A. N. (1995). The third R: refinement. ATLA 23, 332-346.
135. Russell, W. M. S. and Burch, R. L. (1959). The Principles of Humane Experimental Technique. London, UK: Methuen.
136. Sandusky, C. B., Even, M., Stoick, K. and Sandler, J. (2006). Strategies to reduce animal testing in US EPA's HPV programme. ALTEX 23 Sp. Issue, 150-152.
137. Schindler, S., Spreitzer, I., Löschner, B. et al. (2006a). International validation of pyrogen tests based on cryopreserved human primary blood cells. J. Immunol. Methods 316(1-2), 42-51.
138. Schindler, S., Rosenberg, U., Schlote, D. et al. (2006b). Pyrogen testing of lipidic parenterals with a novel in vitro test: application of the IPT based on cryopreserved human whole blood. Pharmeur. Sci. Notes 1, 1-7.
139. Schindler, S., Fennrich, S., Crameri, R. et al. (2007). Fever in the test tube: towards a human(e) pyrogen test. ALTEX 24 Sp. Issue, 60-62.
140. Schrattenholz, A. and Klemm, M. (2007). Neuronal cell culture from human embryonic stem cells as in vitro model for neuroprotection. ALTEX 24(1), 9-15. (Pubitemid 46563940)
141. Schriefer, T. N., Mills, K. R., Murray, N. M. and Hess, C. W. (1988). Evaluation of proximal facial nerve conduction by transcranial magnetic stimulation. J. Neurol. Neurosurg. Psychiat. 51, 60-66.
142. Scialli, A. R. (2008). The challenge of reproductive and developmental toxicology under REACH. Regul. Toxicol. Pharmacol. 51(2), 244-250.
143. Seiler, A., Visan, A., Pohl, I. et al. (2002). Improving the embryonic stem cell test (EST) by establishing molecular endpoints of tissue specific development using murine embryonic stem cells (D3 cells). ALTEX 19 Suppl. 1, 55-63.
144. Seiler, A., Visan, A., Buesen, R. et al. (2004). Improvement of an in vitro stem cell assay for developmental toxicity: the use of molecular endpoints in the embryonic stem cell test. Reprod. Toxicol. 18(2), 231-240. (Pubitemid 38333047)
145. Silliman, C. C. and Wang, M. (2006). The merits of in vitro versus in vivo modelling in investigation of the immune system. Environ. Toxicol. Pharmacol. 21(2), 123-134. (Pubitemid 43168174)
146. Stephens, M. L., Alvino, G. M. and Branson, J. B. (2002). Animal pain and distress in vaccine testing in the United States. Dev. Biol. (Basel) 111, 213-216.
147. Stokes, W. S. (2004). Selecting appropriate animal models and experimental designs for endocrine disrupter research and testing studies. ILAR J. 45(4), 387-393.
148. Taylor, K., Gordon, N., Langley, G. and Higgins, W. (2008). Estimates for worldwide laboratory animal use in 2005. ATLA 36, 327-342.
149. Tennant, R. W., Spalding, J., Stasiewicz, S. and Ashby, J. (1990). Prediction of the outcome of rodent carcinogenicity bioassays currently being conducted on 44 chemicals by the National Toxicology Program. Mutagenesis 5, 3-14. (Pubitemid 20102062)
150. Tsuchiya, T. and Umeda, M. (1995). Improvement in the efficiency of the in vitro transformation assay method using BALB/3T3 A31-1-1 cells. Carcinogenesis 16, 1887-1894.
151. Tsuchiya, T., Umeda, M., Nishiyama, H. et al. (1999). An interlaboratory validation study of the improved transformation assay employing Balb/c 3T3 cells: results of a collaborative study on the two-stage cell transformation assay by the Nongenotoxic Carcinogen Study Group. ATLA 27, 685-702. (Pubitemid 29406672)
152. Ullrich, A., Berg, C., Hengstler, J. G. and Runge, D. (2007). Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion. ALTEX 24(1), 35-40. (Pubitemid 46563942)
153. USDA-APHIS-AC, US Department of Agriculture-Animal and Plant Health Inspection Service-Animal Care (2000). Animal Care Survey: USDA Employee Survey on the Effectiveness of IACUC Regulations. Riverdale, MD, US: USDA-APHIS-AC.
154. US Government Printing Office (1985). The Animal Welfare Act - As Amended. Known as the "Improved Standards for Laboratory Animal" 7 US Code §§2131-2159. Public Law 99-198 7Code of Federal Regulations2.22, 2.80, and 371.2 (g). Washington, DC, US: U.S. Government Printing Office.
155. Vedani, A., Dobler, M. and Lill, M. A. (2005). Virtual test kits for predicting harmful effects triggered by drugs and chemicals mediated by specific proteins. ALTEX 22(3), 123-134. (Pubitemid 41508720)
156. Vedani, A., Lill, M. A. and Dobler, M. (2007a). Predicting the toxic potential of drugs and chemicals in silico. ALTEX 24 Sp. Issue, 63-66.
157. Vedani, A., Dobler, M., Spreafico, M. et al. (2007b). VirtualToxLab - in silico prediction of the toxic potential of drugs and environmental chemicals: evaluation status and internet access protocol. ALTEX 24(3), 153-161.
158. Veith, G. D. (2006). Roles for QSAR in risk assessment. ALTEX 23 Sp. Issue, 369-372.
159. Weibel, F., Andersson, T., Casciano, D. et al. (1997). Genetically engineered cell lines: characterisation and applications in toxicity testing. The Report and Recommendations of ECVAM Workshop 26. ATLA 25, 625-639.
160. Whitlow, S., Bürgin, H. and Clemann, N. (2007). The Embryonic Stem Cell Test for the early selection of pharmaceutical compounds. ALTEX 24(1), 3-7. (Pubitemid 46563939)
161. Wishart, D. S. (2007). Improving early drug discovery through ADME modelling: an overview. Drugs R. D. 8(6), 349-362. (Pubitemid 350014787)
162. Worth, A. P. and Balls, M. (eds.) (2002). Alternative (non-animal) methods for chemicals testing: current status and future prospects. A report prepared by ECVAM and the ECVAM Working Group on Chemicals. ATLA 30 Suppl. 1, 1-125.
163. Zhang, H., Borman, H. D. and Myhr, B. C. (2004). Enhancement of the morphological transformation of Syrian hamster embryo (SHE) cells by reducing incubation time of the target cells. Mutat. Res. 548, 1-7. (Pubitemid 38446875)